Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), A rise of 528,374 shares or 8.3% was seen in the short interest of Vertex Pharmaceuticals Incorporated. Even as the interest increased from 6,346,999 shares on May 31,2016 to 6,875,373 shares on June 15,2016, the days to cover came in at 5. The updated interest stood at 2.8% of the stocks floats. The stock has seen an average daily volume of 1,379,406 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): The stock opened at $83.58 on Friday but the bulls could not build on the opening and the stock topped out at $85.79 for the day. The stock traded down to $81.82 during the day, due to lack of any buying support eventually closed down at $81.90 with a loss of -7.14% for the day. The stock had closed at $88.20 on the previous day. The total traded volume was 2,298,494 shares.
The company shares have dropped -32.89% from its 1 Year high price. On Aug 10, 2015, the shares registered one year high at $143.45 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $88.16 and the 200 Day Moving Average price is recorded at $92.60.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has tumbled 5.57% during the past week and has dropped 9.38% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 4%. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has underperformed the index by 6.64% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.